The urokinase protease system as a target for breast cancer prognosis and therapy: Technical considerations

Journal of Clinical Ligand Assay

Volumn 25, Issue 1, 2002, Pages 43-52

  Schmitt, Manfred ^a   Lienert, S ^a   Prechtel, D ^a   Sedlaczek, E ^a   Welk, A ^a   Reuning, U ^a   Magdolen, V ^a   Janicke F ^a   Sweep, C G J ^a   Harbeck, N ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cancer; CD87; ELISA; PAI 1; Plasminogen activation system; Prognosis; Therapy; Tissue extract; Tumor; UPA; Urokinase; Urokinase receptor

Indexed keywords

ANTINEOPLASTIC AGENT; CATHEPSIN; MATRIX METALLOPROTEINASE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE; SERINE PROTEINASE; UROKINASE;

BLOOD VESSEL; BREAST CARCINOMA; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; ENZYME LINKED IMMUNOSORBENT ASSAY; FROZEN SECTION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; METASTASIS; MORTALITY; PROGNOSIS; PROTEIN DEGRADATION; REPRODUCIBILITY;

EID: 18544370260     PISSN: 10811672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (86)

1. The urokinase plasminogen activator system as a novel target for tumour therapy
2. The urokinase-type plasminogen activator system in cancer metastasis: A review
3. Proteases as prognostic markers in cancer
4. Tumor-associated proteases
5. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
6. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis
7. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas
8. Urokinase-type plasminogen activator antigen and early relapse in breast cancer
9. The urokinase-type plasminogen activator (uPA) is a potent predictor of early relapse in breast cancer
10. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer
11. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1
12. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis
13. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2
14. Co-expression of urokinase, urokinase-receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells
15. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
16. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies
17. Plasminogen activators, tissue degradation, and cancer
18. 2-macroglobulin receptor in human breast carcinomas
19. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry
20. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue
21. The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin
22. Regulation of integrin function by the urokinase receptor
23. Making connections count
24. Both uPA and PAI-1 are independent prognosticators of relapse and death in breast cancer
25. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis
26. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer
27. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay
28. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: Six-year median follow-up
29. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse
30. Urokinase plasminogen activator: A prognostic marker in breast cancer including patients with axillary node-negative disease
31. Dissemination risk index based on plasminogen activator system components in primary breast cancer
32. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
33. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer
34. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer
35. New ELISA for quantitation of human urokinase receptor (CD87) in cancer
36. Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients
37. Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer
38. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer
39. Tumor-associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system
40. Prognostic value of the plasminogen activation system in patients with gastric carcinoma
41. Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer
42. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer
43. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer
44. Strong prognostic impact of tumor-associated urokinase-type plasminogen activatorin completely resected adenocarcinoma of the esophagus
45. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy
46. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
47. Impact of urokinase-type plasminogen activator and its inhibitor type I on prognosis in cervical cancer of the uterus
48. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma
49. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer
50. Prognostic impact of urokinase, urokinase receptor and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue
51. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma
52. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy
53. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice
54. Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression
55. Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: In vitro and in vivo studies of uptake, effects and toxicity
56. In vitro inhibition of human cell line invasiveness by antisense uPA receptor
57. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display
58. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator
59. Cyclo 19,31[D-Cys 19]-uPA 19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87)
60. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides
61. The urokinase-type plasminogen activator system - A new target for tumor therapy
62. Modulators of the urokinase-type plasminogen activation system for cancer
63. Prevention of metastasis by inhibition of the urokinase receptor
64. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody
65. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells
66. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87)
67. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice
68. Antibodies to plasminogen activator inhibit tumor metastasis
69. Plasminogen activator dependent pathway in the dissemination of human tumor cells in the chick embryo
70. Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse
71. Interference with the urokinase plasminogen activator system: A promising therapy concept for solid tumors
72. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 workshop
73. External quality assessment of trans-european multicentre antigen determinations (ELISA) of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer tissue extracts
74. Breast cancer prognostic factors: Evaluation guidelines
75. Do we need prognostic factors in nodal-negative breast cancer? Arbiter
76. Comparative study of four extraction procedures for urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues
77. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins
78. Do we need better prognostic factors in node-negative breast cancer?
79. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer
80. Markers of tumor angiogenesis and proteolysis independently define high-and low-risk subsets of node-negative breast cancer patients
81. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: A prospective study on multicenter basis
82. Low cathepsin D and low plasminogen activator type I inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence
83. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer
84. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
85. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer
86. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients